Physician profile

Kelli M Ruby

Psychiatry · Butler, PA

NPI 1659799427

$489.01

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$14.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $171.62 2019
Avanir Pharmaceuticals, INC. $112.67 2019-2020
Janssen Pharmaceuticals, INC $50.21 2019-2020
Allergan, INC. $30.07 2019
Acadia Pharmaceuticals INC $22.55 2019
Takeda Pharmaceuticals U.S.A., INC. $21.44 2019
Alkermes, INC. $18.78 2020
Ironshore Pharmaceuticals INC. $17.18 2019
Vanda Pharmaceuticals INC. $15.30 2019
Lundbeck LLC $14.96 2019
Abbvie INC. $14.23 2023 Vraylar

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kelli M Ruby

$489.01

in general payments reported 2019-2025

Years
2019-2023
Top company
Otsuka America Pharmaceutical, INC.

https://glasscript.com/doctor/5694769/kelli-m-ruby

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.